Conformal radiotherapy to 76 Gy in localized prostate cancer. Therapeutic modalities and preliminary results;Radiothérapie conformationnelle à 76 Gy des cancers localisés de la prostate. Modalités thérapeutiques et résultats préliminaires

Cancer/Radiotherapie

Volumn 12, Issue 2, 2008, Pages 78-87

  Pontvert, D ^a   Gaboriaud, G ^a   Flam, T ^b   Jourdan Da Silva, N ^a   Thiounn, N ^c   Mammar, H ^a   Beuzeboc, P ^a   Debre B ^b  

^a INSTITUT CURIE   (France)

^b Institut Cochin   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Conformal radiotherapy; Disease free survival; Prostatic neoplasm; Toxicity

Indexed keywords

ANDROGEN;

ARTICLE; BIOCHEMISTRY; BLADDER; BLADDER BLEEDING; CANCER ADJUVANT THERAPY; CANCER CENTER; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED RADIOTHERAPY; CONSENSUS; CONTROLLED STUDY; DISEASE SEVERITY; FOLLOW UP; HUMAN; LYMPH NODE IRRADIATION; MALE; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE; PROSTATE CANCER; RADIATION DOSE; RECTUM; RECTUM HEMORRHAGE; SEMINAL VESICLE; STATISTICAL SIGNIFICANCE;

AGED; AGED, 80 AND OVER; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL;

EID: 41449085347     PISSN: 12783218     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canrad.2007.11.002     Document Type: Article

References (37)

1. American Society for Therapeutic Radiology and Oncology consensus panel. Consensus statement guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37 (1997) 1035-1041
2. Bey P., Carrie C., Beckendorf V., Ginestet C., Aletti P., Madelis G., et al. Dose escalation with 3D-CRT in prostate cancer: french study of dose escalation with conformal 3D radiotherapy in prostate cancer-preliminary results. Int J Radiat Oncol Biol Phys 48 (2000) 513-517
3. Bey P, Carrie C, Ginestet C, Aletti P, Pommier P, Cowen D, et al. French study of dose escalation from 66 to 80 GY with 3D-CRT in prostate cancer: results at 5 years. Proceedings of the 45th annual ASTRO meeting. Int J Radiat Oncol Biol Phys 2003; 57, supplement: S272.
4. Bolla M., Gonzalez D., Warde P., Dubois J.B., Mirimanoff R.E., Storme G., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337 (1997) 295-300
5. Bolla M., Maingon P., Fourneret P., Artignan X., and Descotes J.-L. Place de l'association de radiothérapie et d'hormonothérapie dans les cancers de la prostate. Cancer Radiother 9 (2005) 394-398
6. D'Amico A.V., Whittington R., Malkowicz S.B., Schultz D., Blank K., Broderick G.A., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 11 (1998) 969-974
7. D'Amico A.V., Manola J., Loffredo M., Renshaw A.A., DellaCroce A., and Kantoff P.W. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 292 (2004) 821-827
8. Dearnaley D.P., Khoo V.S., Norman A.R., Meyer L., Nahum A., Tait D., et al. Comparaison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet 353 (1999) 267-272
9. Dearnaley D.P., Hall E., Lawrence D., Huddart R.A., Eeles R., Nutting C.M., et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer 92 (2005) 488-498
10. De Crevoiser R., Lagrange J.L., Messai T., M'Barek B., and Lefkopoulos D. Dispositifs de repositionnement prostatique sous l'accélérateur linéaire. Prostate localization systems for prostate radiotherapy. Cancer Radiother 10 (2006) 394-401
11. Hanks G.E., Schultheiss T.E., Hanlon A.L., Hunt M., Lee W.R., Epstein B.E., et al. Optimisation of conformal radiation treatment of prostate cancer: report of dose escalation study. Int J Radiat Oncol Biol Phys 37 (1997) 543-550
12. Hanks G.E., Hanlon A.L., Schultheiss T.E., Pinover W.H., Movsas B., Epstein B.E., et al. Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions. Int J Radiat Oncol Biol Phys 41 (1998) 501-510
13. Hanlon A.L., and Hanks G.E. Scrutiny of the ASTRO consensus definition of biochemical failure in irradiated prostate cancer patients demonstrates its usefulness and robustness. Int J Radiat Oncol Biol Phys 46 (2000) 559-566
14. ICRU Report no. 50. Prescribing, recording, and reporting photon beam therapy. Washington DC: International commission on radiation units and measurements; 1993.
15. ICRU. Report no. 62 (supplement to ICRU Report 50). Prescribing, recording, and reporting photon beam therapy. Bethesda, MD: International commission on radiation units and measurements; 1999.
16. Jackson A., Skwarchuk M.W., Zelefsky M.J., Cowen D.M., Venkatraman E.S., Levegrun S., et al. Late rectal bleeding after conformal radiotherapy of prostate cancer. II. Volume effects and dose-volume histograms. Int J Radiat Oncol Biol Phys 49 (2001) 685-698
17. Kupelian P.A., Mohan D.S., Lyons J., Klein E.A., and Reddy C.A. Higher than standard radiation doses (> or = 72Gy) with or without androgen deprivation in the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys 46 (2000) 567-574
18. Kupelian P., Kuban D., Thames H., Levy L., Horwitz E., Martinez A., et al. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995. Int J Radiat Oncol Biol Phys 61 (2005) 415-419
19. Laverdière J., Gomez J.L., Cusan L., Suburu E.R., Diamond P., Lemay M., et al. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 37 (1997) 247-252
20. Maingon P., Bolla M., Truc G., Bosset M., Peignaux K., and Ammor A. La radiothérapie de conformation avec et sans modulation d'intensité dans le traitement du cancer localisé de la prostate. Cancer Radiother 9 (2005) 382-387
21. Peeters S.T., Heemsbergen W.D., Koper P.C., Van Putten W.L., Slot A., Dielwart M.F., et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24 (2006) 1990-1996
22. Pilepich M.V., Caplan R., Byhard R.W., Lawton C.A., Gallagher M.J., Mesic J.B., et al. Phase III trial of androgen suppression using goserelin in unfavourable-prognostis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 15 (1997) 1013-1021
23. Pilepich M.V., Winter K., Madhu J.J., Mesic J.B., Sause W., Rubin P., et al. Phase III Radiation Therapy Oncology group (RTOG) Trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advance carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50 (2001) 1243-1252
24. Pollack A., and Zagars. External beam radiotherapy dose response of prostate cancer. Int J Radiat Oncol Biol Phys 39 (1997) 1011-1018
25. Pollack A., Zagars G.K., Starkschall G., Antolak J., Lee J., Huang E., et al. Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53 (2002) 1097-1105
26. Pollack A., Hanlon A.L., Horwitz E.M., Feigenberg S.J., Uzzo R.G., and Hanks G.E. Prostate cancer radiotherapy dose response: an update of the fox chase experience. J Urol 171 (2004) 1132-1136
27. Roach M., Lu J., Pilepich M.V., Asbell S.O., Mohiuddin M., Terry R., et al. Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials. Int J Radiat Oncol Biol Phys 47 (2000) 609-615
28. Roach III M., DeSilvio M., Lawton C., Uhl V., Machtay M., Seider M.J., et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation therapy oncology group 9413. J Clin Oncol 21 (2003) 1904-1911
29. Roach III M., Hanks G., Thames Jr. H., Schellhammer P., Shipley W.U., Sokol G.H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix consensus conference. Int J Radiat Oncol Biol Phys 65 (2006) 965-974
30. Roach III M., DeSilvio M., Valicenti R., Grignon D., Asbell S.O., Lawton C., et al. Whole-pelvis, "mini-pelvis", or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation therapy oncology group 9134 trial. Int J Radiat Oncol Biol Phys 66 (2006) 647-653
31. Shipley W.U., Verhey L.J., Munzenrider J.E., Suit H.D., Urie M.M., MacManus P.L., et al. Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int J Radiat Oncol Biol Phys 32 (1995) 3-12
32. Skwarchuk M.W., Jackson A., Zelefsky M.J., Venkatraman E.S., Cowen D.M., Levegrun S., et al. Late rectal toxicity after conformal radiotherapy of prostate cancer (I): multivariate analysis and dose-response. Int J Radiat Oncol Biol Phys 47 (2000) 103-113
33. Storey M.R., Pollack A., Zagars G., Smith L., Antolak J., and Rosen I. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys 48 (2000) 635-642
34. Thames H.D., Kuban D.A., DeSilvio M.L., Levy L.B., Horwitz E.M., Kupelian P.A., et al. Increasing external beam dose for T1-T2 prostate cancer: effect on risk groups. Int J Radiat Oncol Biol Phys 65 (2006) 975-981
35. Zelefsky M.J., Leibel S.A., Gaudin P.B., Kutcher G.J., Fleshner N., Venkatramen E.S., et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 41 (1998) 491-500
36. Zelefsky M.J., Chan H., Hunt M., Yamada Y., Shippy A.M., and Amols H. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 176 (2006) 1415-1419
37. Zietman A.L., DeSilvio M.L., Slater J.D., Rossi Jr. C.J., Miller D.W., Adams J.A., et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 294 (2005) 1233-1239